Myocardial bridging

Article written and reviewed by Dr Luca Moretti

Myocardial bridging is a congenital variant in which a segment of a coronary artery, most often the left anterior descending artery, temporarily leaves the epicardial surface and runs within the heart muscle. The overlying fibers form the bridge, while the underlying arterial segment is termed tunneled; this intramyocardial anatomy is common and in most cases causes no symptoms. Its presence on an examination therefore does not, by itself, amount to ischemic disease.
During systole, contraction of the myocardium narrows the tunneled segment, producing the classic angiographic milking effect. Because left coronary flow occurs mainly in diastole, exclusively systolic compression may have little consequence; delayed relaxation in early diastole and reduced perfusion time during tachycardia are more important. Dynamic compression depends on heart rate, contractility, and ventricular load. It does not behave like a fixed atherosclerotic stenosis.

A clinical syndrome attributable to the bridge requires concordance among symptoms, anatomy, ischemia, and physiology. Chest pain in someone with an incidental bridge may instead result from proximal plaque, epicardial spasm, microvascular dysfunction, cardiomyopathy, or noncardiac causes; temporal or radiological association does not prove causation. A symptomatic bridge is far less common than the anatomical finding. The diagnosis must also explain why the alternatives are insufficient.
Myocardial bridging must not be confused with the intramural course of an anomalous coronary artery, in which the vessel passes within the aortic wall and is associated with different mechanisms and surgical decisions; furthermore, a known diagnosis does not justify dismissing prolonged pain, sudden dyspnea, syncope, or instability, which require the usual urgent assessment. Anatomical distinction precedes any invasive treatment. Warning signs always take precedence over a preexisting label.

Etiology, risk factors, pathogenesis, and pathophysiology

The bridge results from the congenital organization of the relationship between coronary artery and myocardium during development, not from acquired migration of the artery into the ventricle. It may be recognized in childhood or remain hidden until adulthood, when more sensitive imaging makes it visible or new hemodynamic conditions amplify its effects. A congenital origin does not imply early clinical expression. Hypertrophy, hypertension, and reduced diastolic compliance may reveal previously silent anatomy.
Depth, length, fiber orientation, number of segments, and relationship to septal branches determine how much force is transmitted to the lumen. CCTA often describes superficial, deep, and long bridges, but cutoffs such as a depth of at least 2 mm or length of at least 25 mm are descriptive and useful for planning, not universally validated clinical thresholds. Bridge morphology changes the likelihood of compression. No isolated anatomical measurement proves ischemia or mandates intervention.

Contraction of the overlying fibers reduces the area of the tunneled segment in systole, but in hemodynamically significant bridges the lumen does not recover immediately when the aortic valve opens. The delay extends into early diastole, when the perfusion gradient should supply the left myocardium. Early diastolic relaxation is more relevant than simple systolic squeezing. A dynamic stenosis may therefore reduce flow precisely when demand is high.
Tachycardia and adrenergic stimulation shorten diastole, increase contraction force and oxygen consumption, creating conditions favorable to ischemia; this explains why symptoms emerge mainly during running, stress, fever, or other hyperdynamic states and why dobutamine may reveal physiology that resting adenosine does not. Diastolic reserve decreases as heart rate rises. The effect is not identical in every patient or on every day.

Intracoronary measurements have documented a pressure rise proximally, a sharp distal fall during systole, and sometimes a negative systolic gradient, followed by delayed recovery. Doppler may show early diastolic acceleration with rapid deceleration, the so-called fingertip profile, and brief proximal retrograde flows. The hemodynamic signature reflects complex phasic obstruction; thus, FFR averaged over the whole cycle may mask diastolic impairment or be distorted by systolic pressure.
A bridge over the left anterior descending artery may also alter septal branch perfusion. Physiological models and small studies suggest that during stress some flow is diverted toward the distal epicardial bed, while septal branches upstream of the compression experience an unfavorable gradient, contributing to septal ischemia. Septal steal is a plausible mechanism in selected cases. It is not an inevitable consequence of every bridge visible on CT.

The endothelium and vascular smooth muscle may show abnormal vasoreactivity. Acetylcholine studies have observed vasoconstriction or spasm more often in symptomatic patients, while chronic compression may disturb shear stress in adjacent segments; however, separating cause, consequence, and simple coexistence remains difficult. Vasomotor dysfunction may turn an anatomical finding into a mixed phenotype. Documenting it is essential because it also changes drug selection.
The immediately proximal segment is exposed to oscillatory flow, increased pressure, and low shear stress, conditions that promote endothelial dysfunction and plaque. The tunneled segment tends to be relatively spared from atherosclerosis, probably because of differences in the wall, perivascular environment, and high shear stress, without being biologically invulnerable. Proximal atherosclerosis may become the actual cause of symptoms. Investigating it does not contradict the bridge's nonatherosclerotic nature.

Ventricular hypertrophy, hypertrophic cardiomyopathy, aortic stenosis, hypertension, and diastolic dysfunction increase demand and extravascular pressure. Anemia, hyperthyroidism, and tachyarrhythmias may further reduce reserve, while concomitant microvascular dysfunction limits the distal bed's compensatory capacity. Hemodynamic modifiers explain how symptoms vary over time. Treating them may improve the condition without changing bridge anatomy.

Pathological anatomy, classification, and progression

The left anterior descending artery, especially its mid segment, is involved in the great majority of clinical findings, while bridges over diagonal, circumflex, or right coronary branches are recognized less often. Imaging systems detect different segments with different sensitivity, and small intramyocardial branches may represent normal architecture rather than a defined lesion. The mid-LAD location is the classic phenotype. Number and distribution must be described without multiplying irrelevant diagnoses.
Prevalence estimates change dramatically with method and population. Reviews generally report about 2 to 6 percent with coronary angiography, 19 to 22 percent with CCTA, and more than one third in many autopsy series, differences caused by sensitivity, definitions, and the ability to identify bridges without evident compression; anatomical prevalence does not measure the frequency of ischemic syndrome. Comparing percentages without specifying the technique produces misleading conclusions.

On CT, a complete bridge is surrounded by myocardium, while in a superficial bridge the vessel may be covered only by thin fibers. Depth, length, and distance from epicardial tissues are measured along its course; systolic and diastolic reconstructions may suggest the dynamic component, but the low heart rate and nitrates used for the examination modify its expression. CT classification primarily aids anatomical assessment and planning. It does not replace functional evidence when symptoms remain controversial.
On coronary angiography, the traditional finding is systolic narrowing that lessens in diastole, described as a milking effect or step down-step up. Some reviews define marked narrowing as at least a 70 percent diameter reduction in systole with at least 35 percent residual narrowing in mid or late diastole, but these values are neither universal diagnostic criteria nor validated surgical thresholds. Angiographic milking documents luminal dynamics. Its intensity changes with contractility, vascular tone, and drugs.

The historical Schwarz classification distinguishes type A, an anatomical finding without ischemia; type B, ischemia during stress; and type C, invasive hemodynamic abnormalities. It helps explain the evolution of clinical reasoning but has not been validated as a contemporary algorithm able to predict events or automatically select therapy. The Schwarz classification remains descriptive. Today, multimodal concordance and response to properly conducted treatment are more important.
Intravascular ultrasonography may show a hypoechoic half-moon around the tunneled vessel and document compression during the cardiac cycle. Histological and IVUS studies have demonstrated proximal plaque with relative sparing of the covered segment; however, intimal thickness and remodeling depend on age, risk factors, and selection of patients undergoing a procedure. The half-moon sign supports anatomical identification. Alone, it does not prove that pain is caused by the bridge.

The anatomy does not progress like a plaque: depth and length are substantially stable after development. The functional relationship may change because hypertrophy, fibrosis, increased pressure, diastolic stiffness, and vascular disease alter compressive force and compensatory capacity; deconditioning may also produce tachycardia at lower workloads. Functional progression explains late presentations. Nevertheless, a new symptom requires exclusion of acquired causes before it is attributed to the bridge.
In hypertrophic cardiomyopathy, bridges are recognized more frequently, particularly in childhood, but their independent role in arrhythmias and sudden death remains controversial. A meta-analysis found an association with ischemia without a clear increase in cardiovascular mortality or other events, and the underlying myocardial disease remains a strong confounder. The hypertrophic context requires separate assessment. The risk intrinsic to cardiomyopathy must not be transferred to the general population.

In athletes, a bridge may be found during investigation of pain, ECG abnormalities, or syncope. Maximal heart rate and contractility make greater expression plausible, but causality must be demonstrated and anomalous coronary arteries, cardiomyopathies, and inherited arrhythmias must be excluded; sports assessment incorporates stress resembling the practiced activity. A CT finding alone does not automatically justify permanent exclusion from sport.

Signs and symptoms

The most common presentation is a complete absence of symptoms: the bridge is observed incidentally on CT performed for another reason or during coronary angiography; these people must not be turned into patients because of a common variant, particularly when there is no ischemia, arrhythmia, or concomitant disease; an incidental finding requires explanation and context. Reasoned reassurance avoids unnecessary monitoring and restrictions.
When clinically relevant, the typical complaint is retrosternal pressure or tightness during intense exercise, climbing, emotional stress, or other situations that accelerate the heart. It may be accompanied by dyspnea, fatigue, or reduced performance and tends to improve when the heart slows, although duration and threshold vary. Tachycardia-dependent angina is physiologically consistent. It is not specific enough to distinguish a bridge, plaque, and microvascular dysfunction.

Pain at rest, nocturnal episodes, or circadian variability suggests a vasospastic component, without excluding a concomitant bridge. Symptoms may be prolonged and atypical when sensitization, reflux, or musculoskeletal pain coexist, so the response to a single drug is not a reliable diagnostic test. A resting phenotype requires selective vasomotor investigation. Attributing everything to compression risks physiologically inappropriate treatment.
ST-segment abnormalities, elevated troponin, or infarction have been reported with myocardial bridging, but they are rare presentations and require a complete search for thrombosis, plaque, dissection, embolism, spasm, myocarditis, and Takotsubo syndrome. Anatomical proximity is insufficient to declare the bridge responsible for an acute syndrome. Causality in infarction is a diagnosis of exclusion supported by imaging. Initial management nevertheless follows emergency protocols.

Palpitations may accompany ischemia, an adrenergic response, or an independent arrhythmia. Exertional syncope, presyncope, and documented ventricular tachycardia increase concern but require ECG monitoring, structural imaging, and electrophysiological assessment according to the presentation, because a bridge does not automatically explain every electrical event. Exertional syncope is a warning sign. The arrhythmic link must be demonstrated beyond coincidence.
Symptoms are rare in children and often emerge in the presence of hypertrophic cardiomyopathy or complex coronary anomalies. Pediatric chest pain is predominantly noncardiac, while syncope during activity, arrhythmia, or objective ischemia requires centers experienced in congenital and pediatric disease; a pediatric bridge is not managed by copying adult thresholds. Growth, anatomy, and associated disease modify every decision.

Physical examination and the resting ECG are generally normal. A murmur, signs of hypertrophy, congestion, persistent repolarization abnormalities, or arrhythmias suggest an additional substrate; even a normal echocardiogram does not exclude phasic flow limitation during stress; baseline normality is common. Diagnosis depends on controlled reproduction of the mechanism, not on nonexistent pathognomonic physical findings.
New, severe, or persistent chest pain, major dyspnea, sweating, nausea, syncope, hypotension, or neurological deficits require immediate assistance. A history of bridging does not protect against atherothrombotic infarction, spontaneous coronary artery dissection, pulmonary embolism, or aortic disease, and must not delay ECG and troponin testing. Unstable symptoms change the clinical pathway. Distinction from a usual recurrence is made safely, not at home.

Investigations and diagnosis

The diagnostic pathway begins with a precise question: is the bridge merely present, or does it explain the symptoms? History, physical examination, ECG, blood tests, and echocardiography assess the likelihood of coronary disease, anemia, thyroid disease, ventricular function, hypertrophy, and valve disease; an acute presentation is managed before any elective study. The causal question guides test selection. Accumulating many tests without a sequence does not strengthen attribution.
Transthoracic echocardiography does not reliably visualize a bridge in adults but identifies hypertrophic cardiomyopathy, aortic stenosis, diastolic dysfunction, and regional abnormalities. Late systolic septal buckling with apical sparing during stress has been described in selected series, an interesting finding but not sufficiently validated to diagnose bridging alone. The baseline echocardiogram defines the myocardial context. A stress sign must be interpreted together with anatomy and perfusion.

Coronary CCTA is the most sensitive noninvasive technique for location, length, depth, complete or superficial coverage, and relationship to branches. It also shows proximal plaque, alternative stenoses, and anomalies of origin or course, information essential before possible surgery; the CT anatomical map distinguishes bridging from an intramural aortic course. Quality, dose, and contrast depend on heart rate, rhythm, renal function, and technology.
CT can compare systolic and diastolic phases, but beta-blockers used to slow the heart reduce the very dynamics being sought, while nitroglycerin dilates adjacent segments and may accentuate contrast. Perfusion analysis and CT-FFR have been studied, but validation for a cyclic, stress-dependent stenosis is more limited than for fixed coronary disease. CT-derived function remains complementary. An algorithmic result does not automatically replace appropriate physiological stress.

Coronary angiography shows the milking effect and diastolic recovery in appropriate projections. Intracoronary nitroglycerin may make narrowing more evident because it dilates the nontunneled segment and may increase relative compression; absence of milking at rest does not exclude dynamics that appear at higher heart rate or inotropy. Invasive luminography depicts caliber, not the wall. A percentage of systolic stenosis is not equivalent to attributable ischemia.
IVUS identifies the hypoechoic half-moon, measures area and compression through the cardiac cycle, and visualizes proximal plaque not evident on angiography alone. It requires slow pullback, attention to probe position, and expertise, while optical coherence tomography offers higher intimal resolution but less penetration for assessing depth and overlying muscle. Intravascular imaging resolves selected anatomical uncertainties. It is not routinely performed for every incidental bridge.

Intracoronary Doppler may document abrupt acceleration at the start of diastole, rapid deceleration, and a plateau, creating the fingertip profile, as well as proximal systolic retrograde flow. The signal depends on guidewire stability and measurement location and has no single threshold that can decide treatment. Phasic velocity makes bridge mechanics visible. Pressure and flow must be interpreted in the same hemodynamic context.
Conventional whole-cycle FFR during adenosine was developed for fixed stenoses. In a bridge, distal systolic pressure may exceed proximal pressure and artificially raise the average, while adenosine increases flow without fully reproducing the increased contractility responsible for symptoms; mean FFR may therefore underestimate dynamic limitation. A value above 0.80 alone does not close the case if the clinical physiology remains compelling.

Diastolic FFR excludes systole from the calculation and is measured while heart rate and contractility increase with dobutamine. Small studies have proposed a threshold of 0.76 or less as indicating significance and correlating with stress ischemia, but it derives from selected populations and is not a universal standard validated against clinical outcomes. dFFR with dobutamine is physiologically coherent. Dose, heart rate reached, symptoms, and reproducibility must appear in the report.
Predominantly diastolic or nonhyperemic pressure indices, such as iFR, dPR, and RFR, have been applied at rest and during inotropic stress. They may detect drops attenuated by FFR, but commercial cutoffs derived from atherosclerotic stenoses cannot automatically be transferred to bridging, and protocols remain heterogeneous; nonhyperemic indices are emerging tools. Interpretation requires a laboratory familiar with artifacts and phasic mechanics.

Exercise ECG testing may reproduce pain and ischemic changes, but sensitivity and specificity are limited. Stress echocardiography, SPECT, PET, or magnetic resonance imaging looks for ischemia in the affected arterial territory; exercise or dobutamine better reproduces tachycardia and inotropy, while vasodilators mainly interrogate global reserve and microvascular mechanisms. Stress imaging must match the clinical trigger. A nonterritorial defect calls for an alternative or additional pathophysiology.
In patients with angina and nonobstructive coronary arteries, CFR, IMR, and acetylcholine can identify microvascular dysfunction or epicardial spasm coexisting with the bridge. A positive vasomotor test radically changes the interpretation of resting episodes and caution with certain drugs, while proximal plaque may require its own FFR and prevention. Mechanism-based diagnosis avoids a false either-or choice. Several abnormalities may contribute to different degrees in the same patient.

Elements required to attribute symptoms to myocardial bridging

• Compatible anatomy: a tunneled segment defined by location, length, and depth, distinguished from congenital coronary anomalies.
• Consistent phenotype: symptoms reproducible with tachycardia or inotropy, or another presentation explained by the documented mechanism.
• Territorial ischemia: objective evidence in the same territory, interpreted with the limitations and quality of the method used.
• Dynamic physiology: a diastolic or flow abnormality during appropriate stress when the decision depends on causality.
• Alternatives excluded: plaque, spasm, microvascular dysfunction, cardiomyopathy, and extracardiac causes considered systematically.

The differential diagnosis includes atherosclerotic stenosis, SCAD, vasospasm, microvascular dysfunction, anomalous coronary origin, hypertrophic cardiomyopathy, myocarditis, Takotsubo syndrome, valve disease, and noncardiac pain. A useful report clearly separates anatomical presence, functional significance, and degree of causal certainty. The diagnostic conclusion should not be limited to the word bridge. It must state which data explain the symptoms and which uncertainties remain.

Treatment and prognosis

An incidental bridge without symptoms or ischemia requires no specific drugs, procedures, or serial anatomical imaging. Appropriate measures are an explanation of its congenital nature, ordinary cardiovascular risk management, and instructions about signs warranting reassessment, while avoiding restrictions that promote fear and deconditioning. Clinical observation is an active, proportionate choice. The goal is not to eliminate a common finding but to recognize a genuine syndrome if present.
In symptomatic patients, anemia, hyperthyroidism, hypertension, tachyarrhythmias, and other conditions that increase demand are corrected; plaque, vasospasm, and microvascular dysfunction are treated according to specific indications. Caffeine, stimulants, decongestants, and sympathomimetic substances may worsen tachycardia in sensitive individuals and should be assessed without indiscriminate prohibitions. Aggravating factors are often modifiable. A diary of heart rate, activity, and symptoms helps measure response.

Beta-blockers are generally the first choice for angina attributed to bridging because they slow heart rate, prolong diastole, and reduce contractility and compression. The recommendation is supported by physiological logic, small hemodynamic studies, and experience, not by large randomized trials demonstrating reduced infarction or mortality. Targeted beta-blockade is titrated to symptoms, pulse, and blood pressure. Bradycardia, conduction block, asthma, and intolerance limit dose and selection.
Verapamil or diltiazem are alternatives when beta-blockers are contraindicated or poorly tolerated and are of particular interest when a vasospastic component is documented. These drugs also slow the heart but may cause hypotension, edema, constipation, or atrioventricular block and require caution in systolic dysfunction. Heart-rate-lowering calcium channel blockers treat several selected mechanisms. Dihydropyridines alone may induce reflex tachycardia and do not automatically represent the same strategy.

Ivabradine reduces sinus rate without a marked inotropic effect and is sometimes used off-label when tachycardia control remains insufficient or other drugs are not tolerated. Evidence specific to bridging is limited and does not support standardized use; atrial fibrillation, phosphenes, and bradycardia require monitoring. Selective ivabradine use is a second-line option. It does not correct spasm, plaque, or other causes of angina.
Nitrates may dilate the proximal segment and increase the caliber difference, reduce coronary wall tone, and cause reflex tachycardia, accentuating the milking effect in an isolated bridge; they are therefore not automatic therapy and may worsen symptoms; when documented vasospasm coexists, the balance changes and must be managed by specialists. Caution with nitrates derives from dynamic physiology. An occasional response to the drug neither confirms nor excludes the mechanism.

Aspirin or dual antiplatelet therapy is not indicated solely because a bridge is present, while statins follow plaque burden and cardiovascular risk, not intramyocardial anatomy. An acute coronary syndrome, stent, or other disease may of course create independent indications, with duration and intensity defined by the relevant clinical pathway. Antithrombotic prevention is not prescribed reflexively. Expected benefit and bleeding must relate to a demonstrated diagnosis.
Moderate physical activity, gradual warm-up, and rehabilitation may improve conditioning and the symptom threshold. For competitive athletes, the decision considers maximal ischemia, arrhythmias, syncope, anatomy, and associated heart disease, using tests that reproduce the intensity and actions of the sport; no universal prohibition is based on CT alone. Return to sport is individualized. A stable patient does not benefit from imposed inactivity without evidence.

Response to treatment is measured through episode frequency, activity achieved, adverse effects, and quality-of-life instruments. If pain persists despite adequate heart-rate control, the diagnosis is reviewed before adding drugs or proposing procedures, especially seeking spasm, microvascular disease, and nonischemic causes. Functional follow-up verifies the initial hypothesis. Persistent symptoms do not automatically mean greater anatomical compression.
An invasive strategy is considered only for patients with important symptoms despite tolerated therapy, objective evidence of ischemia, and dynamic physiology attributable to the bridge. The decision requires joint review of CT, angiography, stress testing, and invasive measurements, because incorrect selection exposes patients to risks without resolving pain generated elsewhere. Selection criteria are more important than depth alone. The absence of large trials requires shared decision-making and an expert center.

Stenting the tunneled segment may initially abolish compression but subjects the device to cyclic forces, with risks of restenosis, fracture, thrombosis, perforation, and repeat revascularization. Series are small and outcomes less predictable than PCI for plaque, so this option is generally not preferred. PCI of the bridge remains exceptional. A proximal stent may instead be appropriate for a separate atherosclerotic lesion.
Unroofing, or supra-arterial myotomy, divides the fibers covering the vessel and frees the tunneled segment. Carefully selected surgical series show improved symptoms and quality of life, but some patients retain pain despite no residual ischemia, and randomized comparisons with medical therapy or alternative procedures are unavailable. Surgical unroofing directly treats compression. Depth, length, branches, proximity to the ventricle, and center experience determine feasibility and risk.

Bypass may be considered for very deep or long bridges unsuitable for myotomy, especially when proximal coronary disease coexists, but preserved native flow creates competition and possible graft occlusion. Conduit and target selection lack robust bridge-specific evidence and must be individualized. The risk of competitive flow limits isolated bypass. Surgery must not be equated with surgery for a critical fixed stenosis.
Overall, the prognosis of an incidental finding is favorable. Observational meta-analyses have associated bridging with ischemia and some cardiovascular composites, but heterogeneity, referral patterns, and inadequate control of concomitant mechanisms limit causal inference; treating every bridge has not been shown to prevent serious events; individual prognosis depends on phenotype, not the label. Refractory symptoms deserve care even when the risk of death remains low.

Complications

The most frequent clinical consequence in significant cases is persistent angina with reduced exertion, work absences, and repeated healthcare visits. Inadequate explanation may alternate between false reassurance and excessive alarm, while activity avoidance lowers the tachycardia threshold and amplifies disability; the symptom burden is a real complication. It must be distinguished from the much lower probability of a fatal event.
Plaque tends to concentrate proximal to the bridge and may progress to stenosis or acute coronary syndrome through usual atherothrombotic mechanisms. Risk is also determined by age, lipids, smoking, diabetes, and blood pressure and justifies neither indiscriminate antiplatelet therapy nor statins without their respective indications. Adjacent atherosclerosis requires a separate diagnosis. Wall imaging and functional assessment distinguish fixed and dynamic components.

Epicardial spasm, microvascular spasm, and reduced reserve may coexist and produce resting episodes, ECG abnormalities, or an unexpected drug response. Ignoring this overlap may lead to intensified beta-blockade when targeted vasodilator therapy is needed, or to nitrates in an isolated bridge. The vasomotor phenotype is clinically modifiable. Invasive provocation is reserved for patients in whom the result changes care.
Infarction, local thrombosis, and dissection have been described, especially near the proximal segment, but remain rare and often accompany alternative factors. In an acute event, OCT, IVUS, or magnetic resonance imaging may clarify plaque, thrombus, dissection, or mimics, avoiding use of the bridge as an unverified residual explanation; acute ischemic complications require causal evidence. Treatment is based on the observed mechanism and patient stability.

Ventricular arrhythmias and sudden death appear in case reports and selected cohorts, particularly with ischemia, cardiomyopathy, or intense exercise. The true frequency attributable to an isolated bridge is undefined, and an autopsy association does not prove that the finding caused the event; syncope or documented arrhythmia nevertheless requires thorough assessment. Arrhythmic risk cannot be inferred from depth alone. Myocardial substrate and inherited abnormalities must be excluded.
PCI may be complicated by perforation of the tunneled vessel, dissection, restenosis, thrombosis, and fracture from repeated compression. Even a technically successful procedure may not resolve pain due to spasm or microvascular disease, while dual antiplatelet therapy adds bleeding risk; stent complications explain restrictive selection. Failure does not automatically indicate surgery without renewed verification.

Unroofing carries risks of bleeding, coronary injury, opening of the right ventricle in deep bridges, aneurysm, adhesions, and residual compression if release is incomplete. Modern series from expert centers report low operative mortality, but small samples and favorable selection prevent universal estimates; surgical risk depends on three-dimensional anatomy. Preoperative CT and intraoperative identification of branches reduce avoidable errors.
After surgery, some patients continue to have pain despite negative ischemia tests, indicating a concomitant mechanism or persistent sensitization. A bypass may fail because of competitive flow, and incomplete myotomy may leave compression; follow-up therefore reassesses both anatomy and physiology, avoiding labeling every symptom as recurrent bridging. Postoperative pain requires renewed characterization. A procedure does not guarantee disappearance of every cause of chest symptoms.

Finally, unnecessary invasive tests may cause vasospasm, dissection, arrhythmias, contrast-related kidney injury, or cumulative radiation. At the other extreme, attributing every episode to the known finding may delay diagnosis of a new coronary syndrome, pulmonary embolism, or aortic disease; diagnostic iatrogenesis is prevented by explicit questions. Any change in duration, trigger, intensity, or associated symptoms reopens the differential diagnosis.